While most parents approve of the way their children’s sports organizations are handling coronavirus precautions, more than 1 in 4 are less satisfied with the level of enforcement, a new report suggests. About 28% of parents say their children’s school, travel, or community sports organizations have been “fair” or “poor” in consistently applying COVID-19 precautions, according to the latest national health survey. CS Mott Children’s Hospital.
“‘We are discovering that it is the team sports where the kids come together, obviously many without masks, that are pushing it, rather than the spread in the classroom.’ ”- Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases
A large majority of parents whose children participated in one or more sports said their organization had informed them about the masks and social distancing guidelines, as well as when players should refrain from games or practice due to exposure to the virus. But only 59% said they were told when players needed to be tested. “As more youth sports resume, our survey suggests that parents will need further guidance on whether, when and where their child should be tested,” said survey co-director Sarah Clark in a statement. “This is particularly important as cases are increasing among the very young.”
“‘As more youth sports resume, our survey suggests that parents will need more instruction on whether, when and where their child should be tested.’ ”- Sarah Clark, Co-Director of CS Mott Children’s Hospital National Survey on Child Health
The survey results came shortly after warnings from government health officials, including National Institute of Allergy and Infectious Diseases Director Anthony Fauci, about the potential COVID-19 risk posed by youth sports. “We are discovering that it is the team sports where the kids come together, obviously many without masks, that are pushing it, rather than the spread in the classroom,” Fauci said last Tuesday on “Good Morning America.” “When you go back, you take a look and you try to trace where these clusters of cases come from in the school, it’s just that.” During a briefing at the White House the day before, the director of the Centers for Disease Control and Prevention, Rochelle Walensky, highlighted recent increases in coronavirus cases among young people ages 18 to 24, noting that “Many outbreaks in youth are related to youth sports and extracurricular activities. “This trend, he said,” is why we really want to be vigilant regarding guidance there, as well as testing strategies that could help prevent clusters. “The CDC offers tips and risk mitigation strategies for the playing sports. Although children appear to account for a small fraction of coronavirus hospitalizations and deaths, experts say it will be important to vaccinate them, especially given the potential for more dangerous variants of the virus and the potential for complications such as multisystem inflammatory syndrome. in children (MIS-C), a rare but potentially fatal condition related to COVID-19. Still, a recent survey suggests that only about half of parents with children under the age of 18 say their children are likely to receive the COVID-19 vaccine as soon as it is available for your age group A separate report from the family advocacy organization Parent sTogether noted that “parents report anxiety about unknown side effects as their number one concern, they say they want to know more about the research, and they need more evidence of the vaccine’s safety.” The vaccines currently under authorization for emergency use in the US are licensed for use in persons 18 years of age and older (Moderna MRNA, + 7.17%) or 16 years of age or older (Pfizer PFE, + 0.60% -BioNTech BNTX , + 6.11%), but trials are underway to test the safety and efficacy of COVID-19 vaccines in children. Use of the JNJ vaccine, -1.17% by Johnson & Johnson was halted Tuesday due to concerns about blood clots. Pfizer and BioNTech said in late March that a phase 3 trial of their vaccine in 12-15 year old participants demonstrated 100% efficacy and “robust” antibody responses, surpassing previous results seen in 16 vaccinated trial participants. to 25 years. The two companies also said they had dosed the first healthy children a week earlier in their global phase 1/2/3 study, which aims to evaluate the two-dose vaccine in children ages 6 months to 2 years, 2 to 5 years. years and 5 to 11 years.